Biopharma Has Been Fast To Adopt AI/ML, But It’s Unclear How It Will Play Out
L-R: moderator Rachel Ravens, managing partner, 46Health; Martin Akerman, chief technology officer, Envisagenics; Ahmet-Hamdi Çavuşoğlu, senior director, Merck Digital Sciences Studio; Vitalay Fomin, CEO, Numenos (Alaric DeArment) 
